Mediclinic International plc South African B-BBEE Act: Annual Compliance Report (6666S)

TIDMMDC

RNS Number : 6666S

Mediclinic International plc

27 June 2018

Mediclinic International plc

(Incorporated in England and Wales)

Company Number 8338604

LSE Share Code: MDC

JSE Share Code: MEI

NSX Share Code: MEP

ISIN: GB00B8HX8Z88

LEI: 2138002S5BSBIZTD5I60

("Mediclinic" or "the Company")

27 June 2018

BROAD-BASED BLACK ECONOMIC EMPOWERMENT ACT: ANNUAL COMPLIANCE REPORT

In accordance with the JSE Listings Requirements, applicable to the Company having a secondary listing on the JSE, notice is hereby given that the Company's annual compliance report in terms of section 13G(2) of the South African Broad-Based Black Economic Empowerment Act, 53 of 2003, as amended, (the "B-BBEE Act") was submitted to the Broad-Based Black Economic Empowerment Commission (the "BEE Commission"). The compliance report is available in the governance section of Mediclinic's website at www.mediclinic.com.

The compliance report relates to the assessment of the broad-based black economic empowerment status of Mediclinic Southern Africa (Pty) Ltd, a wholly-owned subsidiary of the Company, in respect of the Company's operations in South Africa.

About the B-BBEE Act

The B-BBEE Act was enacted to establish a legislative framework for the promotion of broad-based black economic empowerment in South Africa and is intended to encourage transformation by including black people in the economy. It covers aspects such as ownership, management control, skills development, enterprise and supplier development and social-economic development. Although compliance with the B-BBEE Act and the Codes of Good Practice issued in terms thereof is voluntary, an obligation was introduced by way of an amendment to the B-BBEE Act in 2013, which became effective in June 2016, to require public companies listed on the JSE to report on their broad-based black economic empowerment status to the BEE Commission.

About Mediclinic International plc

Mediclinic is an international private healthcare services group with operating divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab Emirates. Its core purpose is to enhance the quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, an LSE-listed and UK-based private healthcare group.

Mediclinic comprises 75 hospitals and 28 clinics. Hirslanden operates 17 private acute care facilities and 4 clinics in Switzerland with more than 1 800 inpatient beds; Mediclinic Southern Africa operates 49 hospitals and 2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 100 inpatient beds in total; and Mediclinic Middle East operates 6 hospitals and 22 clinics with more than 700 inpatient beds in the United Arab Emirates.

Mediclinic has a primary listing on the Main Market of the LSE in the United Kingdom, with secondary listings on the JSE in South Africa and the NSX in Namibia.

For further information, please contact:

Company Secretary, Link Company Matters Limited

Jayne Meacham / Caroline Emmet

[phone]

Investor Relations, Mediclinic International plc

James Arnold, Head of Investor Relations

[e-mail]

[phone]

Media queries

FTI Consulting

Brett Pollard/Debbie Scott - UK

[phone]

Sherryn Schooling - South Africa

[phone]

Registered address: 6(th) Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom

Website: www.mediclinic.com

Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank

JSE sponsor: Rand Merchant Bank (A division of FirstRand Bank Limited)

NSX sponsor: Simonis Storm Securities (Pty) Ltd

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCFFMFTMBBTBMP

(END) Dow Jones Newswires

June 27, 2018 07:00 ET (11:00 GMT)